

2019 Resistant Pseudomonas aeruginosa Infections R&D Pipeline Drugs, Companies, Trials and Developments

<https://marketpublishers.com/r/2EC244B6C01EN.html>

Date: March 2019

Pages: 55

Price: US\$ 2,199.00 (Single User License)

ID: 2EC244B6C01EN

Abstracts

The global demand for Resistant Pseudomonas aeruginosa Infections treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Resistant Pseudomonas aeruginosa Infections are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Resistant Pseudomonas aeruginosa Infections pipeline companies from advancing their products.

Resistant Pseudomonas aeruginosa Infections Report Description

The H1-2019 pipeline review report on Resistant Pseudomonas aeruginosa Infections is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.

The Resistant Pseudomonas aeruginosa Infections pipeline guide presents information on all active drugs currently being developed for Resistant Pseudomonas aeruginosa Infections. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Resistant Pseudomonas aeruginosa Infections pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such

as orphan drug status, fast track designation, grants awarded, etc are presented for all Resistant *Pseudomonas aeruginosa* Infections drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Resistant *Pseudomonas aeruginosa* Infections product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Resistant *Pseudomonas aeruginosa* Infections pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Resistant *Pseudomonas aeruginosa* Infections pipeline report includes-

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Resistant *Pseudomonas aeruginosa* Infections pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Resistant *Pseudomonas aeruginosa* Infections pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Resistant *Pseudomonas aeruginosa* Infections pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE OVERVIEW

Key Findings, 2019
Disease Overview
Report Guide and Research Methodology

EXECUTIVE SUMMARY

Resistant Pseudomonas aeruginosa Infections Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Resistant Pseudomonas aeruginosa Infections pipeline, H1@2019
Mechanism of Action wise Resistant Pseudomonas aeruginosa Infections Pipeline Candidates

AMPLIPHI BIOSCIENCES CORP RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile
Drug Details
 Drug Snapshot
 Originator
 Collaborator/Co-Developer
 Route of Administration
 Orphan Drug/Fast Track/Special Designation
 Area
 Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

BIOLYTICS PHARMA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

CONTRAFECT CORP RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

CSA BIOTECH LLC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile
Drug Details
 Drug Snapshot
 Originator
 Collaborator/Co-Developer
 Route of Administration
 Orphan Drug/Fast Track/Special Designation
 Area
 Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

INHIBRX INC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile
Drug Details
 Drug Snapshot
 Originator
 Collaborator/Co-Developer
 Route of Administration
 Orphan Drug/Fast Track/Special Designation
 Area
 Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

LEGOCHEM BIOSCIENCES INC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile
Drug Details
 Drug Snapshot

Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

MELINTA THERAPEUTICS INC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

MID-ATLANTIC BIOTHERAPEUTICS, INC. RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration

Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

NOVARTIS AG RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

SHIONOGI & CO LTD RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS PIPELINE DETAILS

Business Profile
Drug Details
Drug Snapshot
Originator
Collaborator/Co-Developer
Route of Administration
Orphan Drug/Fast Track/Special Designation
Area
Type of Molecular Entity

Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

LATEST RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUG PIPELINE DEVELOPMENTS, 2019

APPENDIX

About Us
Sources and Methodology
Contact Information

I would like to order

Product name: 2019 Resistant Pseudomonas aeruginosa Infections R&D Pipeline Drugs, Companies, Trials and Developments

Product link: <https://marketpublishers.com/r/2EC244B6C01EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2EC244B6C01EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

